Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3]. CHC cure is a crucial event in the prognosis of the disease, since prevents fibrosis progression, decreases the risk of hepatocellular carcinoma (HCC), and improves survival. Standard antiviral therapy with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) has long been the standard of care, despite its limited efficacy and increased ribavirin induced hematological adverse events in thalassemic patients [4]. Recently, several novel highly effective direct antiviral agents (DAAs) have been approved for HCV treatment, with impressive cure rates, higher than 90%, after 8–12 weeks of therapy and mild adverse events [5], but there are no published reports documenting the efficacy, safety and impact on QOL of available interferon-free antiviral regimens in patients with βthalassemia major

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major / Biliotti, Elisa; Palazzo, Donatella; Serani, Marco; Silvestri, Alessandro M.; Volpicelli, Lorenzo; Esvan, Rozenn; Franchi, Cristiana; Spaziante, Martina; Sorrentino, Francesco; Taliani, Gloria. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 96:6(2017), pp. 1043-1045. [10.1007/s00277-017-2986-x]

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major

BILIOTTI, ELISA;PALAZZO, DONATELLA;ESVAN, ROZENN;FRANCHI, CRISTIANA;SPAZIANTE, MARTINA;TALIANI, Gloria
2017

Abstract

Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3]. CHC cure is a crucial event in the prognosis of the disease, since prevents fibrosis progression, decreases the risk of hepatocellular carcinoma (HCC), and improves survival. Standard antiviral therapy with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) has long been the standard of care, despite its limited efficacy and increased ribavirin induced hematological adverse events in thalassemic patients [4]. Recently, several novel highly effective direct antiviral agents (DAAs) have been approved for HCV treatment, with impressive cure rates, higher than 90%, after 8–12 weeks of therapy and mild adverse events [5], but there are no published reports documenting the efficacy, safety and impact on QOL of available interferon-free antiviral regimens in patients with βthalassemia major
File allegati a questo prodotto
File Dimensione Formato  
Biliotti_interferon-free_2017.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 171.16 kB
Formato Adobe PDF
171.16 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/967261
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact